Expression of p-AKT characterizes adenoid cystic carcinomas of head and neck with a higher risk for tumor relapses.
Expression of p-AKT characterizes adenoid cystic carcinomas of head and neck with a higher risk for tumor relapses.
复制标题
DOI：
10.1186/1746-1596-4-18
复制
发表时间：
2009-06-19
影响因子：
2.6
通讯作者：
Schmidt M
中科院分区：
文献类型：
--
作者：
Völker HU;Scheich M;Berndt A;Haubitz I;Metzger A;Müller-Hermelink HK;Kämmerer U;Schmidt M
腺样囊性癌是一种罕见的肿瘤，临床过程缓慢，但经常局部复发。识别具有较高复发风险的肿瘤似乎是有趣的。因此，我们研究了葡萄糖代谢的参数，这被发现与其他恶性肿瘤的预后不良。用抗p-AKT、TKTL-1（转酮酶样1）、M2 PK（M2丙酮酸激酶）和GLUT-1的抗体对29例患者的标本进行免疫化学研究。通过用Ki 67染色来研究增殖。肿瘤位于大、小涎腺。仅研究了典型的筛状亚型。肿瘤的初始分期为pT 1或pT 2。多因素分析显示p-AKT表达与复发风险显著相关（P = 0.036）。M2 PK低表达无显著性（P = 0.065）预示着较高的风险。TKTL-1和GLUT-1在大多数病例中表达，尽管与复发风险无关。p-AKT阳性的腺样囊性癌显示较高的复发风险。然而，在此研究的其他葡萄糖代谢参数或增殖（Ki 67）在该实体中不具有预测性。我们的研究结果证明了靶向抑制PI 3 K/AKT通路的治疗方法的可能背景。
Adenoid cystic carcinomas are rare tumors with an indolent clinical course, but frequent local relapses. The identification of tumors with a higher relapse risk seems to be interesting. Hence we investigated parameters of glucose metabolism, which were found associated with poor prognosis in other malignancies. Specimen of 29 patients were investigated immunohistochemically with antibodies against p-AKT, TKTL-1 (transketolase-like 1), M2PK (M2 pyruvate kinase), and GLUT-1. Proliferation was investigated by staining with Ki67. The tumors were located at the major or minor salivary glands. Only the typical cribriform subtype was investigated. The initial tumor stage was pT1 or pT2. Expression of p-AKT was significantly (P = 0.036) associated with a higher relapse risk in multivariate analysis. Low expression of M2PK was non-significantly (P = 0.065) predictive for a higher risk. TKTL-1 and GLUT-1 were expressed in the majority of cases, albeit not associated with relapse risk. Adenoid cystic carcinomas positive for p-AKT show a higher relapse risk. However, other parameters of glucose metabolism investigated here or proliferation (Ki67) were not predictive in this entity. Our findings demonstrate a possible background for therapeutic approaches targeting the inhibition of PI3K/AKT pathway.
登录
查看更多内容
影响因子：
4.8
作者：
Pfeffer, M. Raphael;Talmi, Yoav;Levitt, Mark
通讯作者：
Levitt, Mark
影响因子：
6.2
作者：
Kunkel, M;Reichert, TE;Whiteside, TL
通讯作者：
Whiteside, TL
影响因子：
1.3
作者：
Weiner, MF;Miranda, RN;De Las Casas, LE
通讯作者：
De Las Casas, LE
影响因子：
3
作者：
SPIRO, RH;HUVOS, AG;STRONG, EW
通讯作者：
STRONG, EW
DOI：
10.1111/j.1447-0756.2008.00749.x
发表时间：
2008-06-01
影响因子：
1.6
作者：
Kohrenhagen, Nico;Voelker, Hans U.;Kammerer, Ulrike
通讯作者：
Kammerer, Ulrike